A new radiation therapy treatment developed for head and neck cancer patients

	Tweet

Most head-and-neck cancers that recur locally after prior full-dose conventional radiation therapy respond to Boron Neutron Capture Therapy (BNCT). These results were obtained in a Phase I/II study at the Helsinki University Hospital, Finland. The scientific director of the research program, professor Heikki Joensuu, University of Helsinki, considers the results clinically significant and very interesting. They open a new field for BNCT, since thus far BNCT has been evaluated only in the treatment of some brain tumours.

The follow-up results of 12 patients diagnosed with cancer of the head-and-neck and treated in a prospective clinical trial were reported in the International Journal of Radiation Oncology, Biology & Physics. 

All patients had cancer of the head-and-neck that had recurred locally after surgery and conventional radiation therapy. Ten out of the 12 patients had substantial tumour shrinkage following BNCT, and in 7 cases the tumour disappeared completely. Adverse effects of treatment were moderate and resembled those of conventional radiation therapy.

The study has been expanded, and up to 30 subjects will now be allowed to enter the study protocol.

Boron neutron capture therapy (BNCT) is a form of targeted radiation treatment for cancer. It is still considered experimental. In this method a boron-containing compound (boronophenylalanine) is first infused into a peripheral vein, following which the compound accumulates in cancer tissue. Cancer is subsequently irradiated with neutrons obtained from a nuclear reactor, which causes boron atoms to split within the cancerous tissue as a result from a boron neutron capture reaction. The resulting smaller particles cause a large radiation effect within the tumour tissue, which destroys cancer cells.

The technique allows targeting of a high dosage of radiation to the tumour while allowing sparing of the adjacent normal tissues from the highest doses of radiation. Boron-mediated targeting of radiation allows treatment of patients who can no longer be treated with conventional radiation therapy. BNCT is administered as single one-day treatment that may be repeated.

The study was sponsored by Boneca Corporation, the spinoff company operating on the medical campus of the Helsinki University and the University Central Hospital (http://www.boneca.fi). The treatments are carried out in collaboration with the Department of Oncology, Helsinki University Central Hospital, at the BNCT facility constructed at the VTT research nuclear reactor site located at Otaniemi, Espoo. The neutron radiation used in the treatment is provided by VTT.

Boneca Corporation’s clinical research program includes also a phase I/II study that evaluates BNCT in the treatment of primary glioblastoma (a highly malignant brain tumour) and another clinical trial that assesses safety and efficacy of BNCT in the treatment of glioblastomas and anaplastic astrocytomas (a type of brain tumour) that have recurred after conventional radiation therapy.

“Our plan is to investigate BNCT in the treatment of cancers located elsewhere in the body that cannot be effectively managed by any known treatment,” says professor Heikki Joensuu.

”The current treatment is a result of a long period of research, a proof of academic expertise, and a model for effective collaboration between Helsinki University Central Hospital, University of Helsinki, VTT Technical Research Centre of Finland, and the company”, says Boneca Corporation’s managing director Markku Pohjola.

###

Boneca Corporation is the only health care company focusing on BNCT in the world. Over one hundred cancer patients have received BNCT at its facilities.

Contact: Professor Heikki Joensuu

358-947-173-208
University of Helsinki

RELATED STORIES:
Tobacco and alcohol use independently increase risk of head and neck cancer   UCSD First to Treat Brain Cancer with Viral Vector   Vaccine against deadly brain cancer shows promise   ‘Timing is everything’ in ensuring healthy brain development   UVA Brain Cancer Trials Lead to FDA Accelerated Approval of Medication   Antidepressant may help head/neck cancer patients   New Surgery Improves Head & Neck Cancer Treatment   Radiation better than surgery at preserving speech for patients with head and neck cancer   Cancer sequencing initiative discovers mutations tied to aggressive childhood brain tumors   Personalized gene therapies may increase survival in brain cancer patients   Acupuncture Reduces Pain and Dysfunction in Head and Neck Cancer Patients After Neck Dissection   Factors behind head and neck cancer revealed   Researchers Identify Best Treatments for Long-Term Survival in Brain Tumor Patients   Researchers Discover Non-Surgical Test for Brain Cancer   Coffee may cut risk of head and neck cancers   Minimizing side effects from chemoradiation could help brain cancer patients live longer   Tobacco use linked to worse outcomes in HPV-positive head and neck cancer, U-M study finds   Ten Minutes That Could Save Your Life   Prenatal Vitamins May Reduce Risk of Brain Tumors in Children   Genetic Risk Factor Found for Head and Neck Cancer in Smokers   Study finds 231 new genes associated with head and neck cancer   Head & neck cancer in transplant patients: For better or worse?

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]